Abstract

: Hyper-coagulability followed by cardiovascular disease is the most common cause of mortality in CKD (chronic kidney disease). Diagnostic usefulness of hypercoagulability marker at various stages of CKD needs to be assessed. : An observational cross-sectional study.: Dept of Biochemistry, Institute of Nephrourology, Bangalore, India from January 2022 to March 2022.Study population consists of CKD patients attending Nephrology outpatient for follow up. They were categorized into 5 stages using eGFR values. Laboratory test including D-Dimer was assayed in all the participants using Abbott Architect ci4100 analyzer. In our study, a peaked and statistically significant (P value = <0.0001) D-Dimer values were observed in stage 4&5 (5.4 ±2.5) in comparison with stage 1, 2 & 3 (0.9±0.2). D- Dimer had strong negative correlationR= - 0.79 with eGFR in stage 5 CKD. D-Dimer assay should be considered as a part of routine investigations in CKD patients especially in developing countries like India, where most of the patients reach hospital only at the later stages of the disease, in order to achieve a better follow-up and management of the disease.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call